Zim Laboratories Ltd
Zim Laboratories Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Steady growth expected in Oral Thin Films (OTF), with significant revenue anticipated in FY27 due to new partnerships and increased local manufacturing focus. FY27 growth is expected despite ongoing geopolitical and regulatory challenges, with revenue growth projected from NIP and OTF products, especially from rest of world (RoW) and pharmerging markets (Pages 28, 29).
From Zim Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Steady growth expected in Oral Thin Films (OTF), with significant revenue anticipated in FY27 due to new partnerships and increased local manufacturing focus.
- NIP (Novel Innovative Products) and OTF businesses projected to grow in FY27 despite EU GMP delays, driven by dossier approvals in RoW and pharmerging markets.
- Target to have 50% of business from NIP and OTF innovative products, with ~30% from regulated markets and ~20% from RoW/pharmerging markets in coming years.
- Anticipated 10-15% annual overall revenue growth, with margins improving to mid to upper teens percentage post-CAPA remediation and EU GMP approval.
- Full commercialization of 17 NIP plus OTF products expected within 24 months, supporting sustained revenue ramp-up.
2 more points from Zim Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Zim Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Majority of CapEx related to 17 innovative products (NIP and OTF) is near completion; only last stages left, no significant further investment anticipated.
- Recent preferential allotment of INR 35 crore raised for three main projects: dedicated enzyme NIP suite, nutraceutical plant expansion, and CAPA remediation.
- Enzyme product CapEx largely completed, currently only maintenance CapEx planned.
- New block/facility created to cater to increased capacity for certain products, though existing plants can also manufacture.
- No plans to increase borrowings further; prefer issue money to be used for CapEx.
2 more points from Zim Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zim Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly provide specific figures or details about the current or expected order book or pending orders for Zim Laboratories Limited as of Q4 FY26.
- However, it is noted that the company is awaiting EU GMP certification, expected within 2-3 months from the call date (May 2026), which will enable commercial orders, especially for new innovative products (NIP) and Oral Thin Films (OTF).
- Commercialization of 17 products within the next 24 months is projected, conditional on regulatory approvals and EU GMP certification.
- The company expects significant revenue growth from OTF this year due to strategic partnerships, particularly in the Middle East.
- Post EU GMP certification, NIP products are expected to start generating revenue in Q4 FY27.
2 more points from Zim Laboratories Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Zim Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹105 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zim Laboratories's management said in earlier quarters
Arthneeti Pro · Annual
Zim Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zim Laboratories Ltd Q4 FY26 results?
Steady growth expected in Oral Thin Films (OTF), with significant revenue anticipated in FY27 due to new partnerships and increased local manufacturing focus. FY27 growth is expected despite ongoing geopolitical and regulatory challenges, with revenue growth projected from NIP and OTF products, especially from rest of world (RoW) and pharmerging markets (Pages 28, 29).
What is Zim Laboratories Ltd share price analysis?
Zim Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 141.2 with a market cap of ₹614 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zim Laboratories Ltd planning capital expenditure?
Majority of CapEx related to 17 innovative products (NIP and OTF) is near completion; only last stages left, no significant further investment anticipated.
Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.